<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CAR T-NK cell therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/car-t-nk-cell-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 01 Apr 2025 20:32:19 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>CAR T-NK cell therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Leveraging CAR Technology to Combat Acute Myeloid Leukemia</title>
		<link>https://bioengineer.org/leveraging-car-technology-to-combat-acute-myeloid-leukemia/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 01 Apr 2025 20:32:19 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AML CAR technology advancements]]></category>
		<category><![CDATA[CAR T-NK cell therapy]]></category>
		<category><![CDATA[cord blood-derived NK cells]]></category>
		<category><![CDATA[HLA-DRB1-targeted immunotherapy]]></category>
		<category><![CDATA[post-allogeneic HCT relapse treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/leveraging-car-technology-to-combat-acute-myeloid-leukemia/</guid>

					<description><![CDATA[In a groundbreaking development in the field of cancer therapy, researchers from The University of Osaka have unveiled promising advancements in the treatment of relapsed acute myeloid leukemia (AML) utilizing chimeric antigen receptor (CAR) T cells and cord blood-derived natural killer (NK) cells. This innovative approach focuses on the molecule known as HLA-DRB1, which has [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">239764</post-id>	</item>
	</channel>
</rss>
